title: Temozolomide/PLGA microparticles: a new protocol for treatment of glioma in rats.
abstract: Implantable and poly (d,l-lactide-co-glycolide) (PLGA) microparticles were developed to deliver temozolomide (TM) continuously in interstitial chemotherapy for glioma. The therapeutic effect of temozolomide/PLGA was evaluated in a rat C6 glioma model. C6 cells were implanted orthotopically into 100 rat brains in 5 groups (n=20 each): sham operation group, control group, local delivery of blank PLGA microspheres group, oral TM group, and local delivery of TM/PLGA group. Rats in oral TM group were orally administered temozolomide, and rats in TM/PLGA group were locally implanted with TM/PLGA microspheres. Ten rats were selected randomly from each group for observing the survival time, and the other 10 rats were killed on POD 14 to measure proliferation activity and apoptosis of the gliomas. Head MRI examination was performed before the rats were killed. The median survival time of sham operation group, control group, blank PLGA microspheres group, oral TM group, and TM/PLGA group was 19.5, 20, 19, 27, and 46.5 days, respectively. MRI demonstrated that the tumor volume was reduced in oral TM group and interstitial TM/PLGA group. PCNA-positive cell staining showed that proliferation activity of tumor cells treated with interstitial TM/PLGA therapy significantly decreased when compared with that of tumor cells treated with oral TM therapy. The apoptosis of C6 cells in interstitial TM/PLGA group significantly increased when compared with that in oral TM group. Interstitial TM/PLGA was effective in treating intracranial C6 rat gliomas and could prove to be a potential chemotherapy agent for human malignant gliomas.
authors.affiliation: Department of Neurosurgery, Second Military Medical University Changhai Hospital, and Department of Pharmaceutics, Second Military Medical University School of Pharmacy, Shanghai, China.
authors.forename: Yu-Hui
authors.initials: YH
authors.lastname: Zhang
authors.forename: He
authors.initials: H
authors.lastname: Zhang
authors.forename: Jian-min
authors.initials: JM
authors.lastname: Liu
authors.forename: Zhi-Jian
authors.initials: ZJ
authors.lastname: Yue
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D017209:Apoptosis / Q000187:drug effects; D001932:Brain Neoplasms / Q000188:drug therapy*; D003606:Dacarbazine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D005910:Glioma / Q000188:drug therapy*; D020287:In Situ Nick-End Labeling; D019344:Lactic Acid / Q000008:administration & dosage*; D008863:Microspheres; D011100:Polyglycolic Acid / Q000008:administration & dosage*; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D051381:Rats; D000077204:Temozolomide
chemical_list: D000970:Antineoplastic Agents; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid; D003606:Dacarbazine; D000077204:Temozolomide
references.citation: Biomaterials. 1993 May;14(6):470-8
references.pmid: 8507795
references.citation: Cancer Chemother Pharmacol. 2003 Dec;52(6):459-64
references.pmid: 13680160
references.citation: Cancer. 1993 Apr 15;71(8):2585-97
references.pmid: 8453582
references.citation: Neuroepidemiology. 2009;32(1):21-9
references.pmid: 18997474
references.citation: J R Soc Interface. 2008 Sep 6;5(26):957-75
references.pmid: 18477539
references.citation: Ann Surg Oncol. 2008 Nov;15(11):3272-7
references.pmid: 18712569
references.citation: Ann Rheum Dis. 2005 Aug;64(8):1132-6
references.pmid: 15695536
references.citation: Expert Opin Drug Saf. 2009 Jul;8(4):493-9
references.pmid: 19435405
references.citation: Cancer Chemother Pharmacol. 2007 Oct;60(5):643-50
references.pmid: 17256133
references.citation: Crit Rev Ther Drug Carrier Syst. 1995;12(1):1-99
references.pmid: 8521523
references.citation: N Engl J Med. 2008 Jul 31;359(5):492-507
references.pmid: 18669428
references.citation: J Diabetes Sci Technol. 2008 Nov;2(6):1003-15
references.pmid: 19885290
references.citation: Int J Radiat Oncol Biol Phys. 2008 Jul 15;71(4):999-1005
references.pmid: 18258384
references.citation: J Neurooncol. 2009 Sep;94(2):203-12
references.pmid: 19337695
references.citation: Clin Cancer Res. 1999 Feb;5(2):309-17
references.pmid: 10037179
references.citation: Cell Transplant. 2008;17(4):409-15
references.pmid: 18522243
references.citation: Int J Pharm. 2007 Feb 1;329(1-2):122-8
references.pmid: 17000068
references.citation: Cancer Treat Rev. 1997 Jan;23(1):35-61
references.pmid: 9189180
references.citation: J Clin Oncol. 1999 Sep;17(9):2762-71
references.pmid: 10561351
references.citation: Ann Surg Oncol. 2008 Oct;15(10):2887-93
references.pmid: 18636295
references.citation: Anticancer Res. 2009 Mar;29(3):911-7
references.pmid: 19414327
references.citation: Br J Cancer. 2000 Sep;83(5):588-93
references.pmid: 10944597
references.citation: Semin Oncol. 2003 Dec;30(6 Suppl 19):4-9
references.pmid: 14765377
references.citation: Cell Transplant. 1999 Jan-Feb;8(1):47-58
references.pmid: 10338275